Outset Medical

Outset Medical, Inc. is a medical technology company, which provides dialysis solutions to patients and healthcare providers. Its product Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Outset Medical reports strong Q1 performance and eyes home dialysis market for growth

Outset Medical's Q1 2023 performance exceeded expectations, with strong revenue growth and margin expansion. The company faces challenges related to hospital insourcing and changing care paradigms but sees opportunities in the home dialysis market and product development. Overall, the company is well-positioned for continued growth and margin improvement.

Outset Medical reports strong Q2 results, confident in revenue guidance

Outset Medical's Q2 2023 earnings call highlighted strong performance, with revenue growth and margin expansion. Despite challenges related to TabloCart shipments, the company remains confident in its 2023 revenue guidance. Opportunities lie in sustaining demand for Tablo and expanding utilization and economic analysis.

Outset Medical reports 9% revenue growth in Q3 2023 earnings

Outset Medical's Q3 performance showed revenue growth and a focus on cost reduction. The company highlighted its strengths in potential CAGR, product superiority, and market expertise. Challenges include competitive noise and a conservative outlook for 2024, while opportunities lie in U.S. dialysis market growth and international expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Outset Medical has seen continued commercial traction and provides a comforting guidance for 2021. While the guidance is strong, I still believe it might be conservative given the recent commercial traction and potential of the home market.

Outset Medical: Continues To Impress

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), the medical technology company that pioneered the Tablo Hemodialysis System, a first-of-its-kind device to reduce the cost and complexity of dialysis, is strengthening its consumer focus with the appointment of Andrea Saia to its board of directors. Saia's background in building iconic global brands will help Outset's efforts to grow the home dialysis market and empower patients to take better charge of their healt

Outset Medical Appoints Global Consumer Brand Builder Andrea Saia to Board of Directors

American Well Corporation

Athira Pharma

Broadstone Net Lease

COMPASS Pathways

Coupang

Dyne Therapeutics

GreenBox POS

908 Devices

Metacrine

Poshmark

Pactiv Evergreen

StepStone Group

Sumo Logic

Vitru Limited

The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14.

U.S. IPO Week Ahead: The Spring IPO Market Starts To Thaw In An 8 IPO Week

Outset Medical, Inc. (OM) CEO Leslie Trigg on Q4 2020 Results - Earnings Call Transcript

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2020. Recent Highlights Recorded net revenue of $17.2 million in the fourth quarter and $49.9 million for the full year of 2020, representing 143% and 231% increases respectively, over the corresponding periods

Outset Medical Reports Fourth Quarter and Full Year 2020 Financial Results

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full year of 2020 after the close of trading on Tuesday, March 9, 2021. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chief Executive Officer, and Rebecca Chambers, Chief Financial Offic

Outset Medical to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021

ResMed

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, is bolstering its board of directors with the appointment of Karen Drexler. Drexler currently serves on the boards of ResMed (NYSE: RMD), a $31B data-driven sleep and respiratory market leader; VIDA Diagnostics, developer of AI-powered lung intelligence and imaging solutions; and Tivic Health, a bioelec

Outset Medical Appoints Karen Drexler to Board of Directors

Discover how Outset Medical is making dialysis easier and cheaper.

Outset Medical Is Trying to Upend Dialysis. What Should Investors Think of This IPO?

Eargo

Nano-X Imaging

Silk Road Medical Inc

Transmedics Group Inc

LONDON--(BUSINESS WIRE)--Deep Pharma Intelligence names Nanox Imaging (NASDAQ:NNOX), TransMedics, Inc. (NASDAQ: TMDX), Outset Medical, Inc. (NASDAQ:OM), Eargo, Inc. (NASDAQ:EAR), and Silk Road Medical, Inc. (NASDAQ:SILK) as best Health-Tech companies to watch in 2021-2022. The report provides an overview and brief assessment of 5 highly impactful and promising medical hardware technologies to be watched in 2021-2022, and the companies behind their development and commercialization. In the case

Deep Pharma Intelligence Names Nanox, TransMedics, Outset, Eargo, and Silkroad as Best Health-Tech Companies to Watch in 2021-2022

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the pricing of an underwritten public offering of 4,000,000 shares of its common stock by certain of its stockholders at a public offering price of $53.00 per share. In addition, such selling stockholders granted the underwriters a 30-day option to purchase up to an additional 600,00

Outset Medical Announces Pricing of Secondary Public Offering

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical Announces Secondary Offering of Common Stock

Outset Medical Announces Secondary Offering of Common Stock

Outset Medical is performing in line with my expectations which I outlined at the time of the public offering. I look forward to the contribution from the home market in 2021, expected to have a huge impact on the top line.

Outset Medical - Looking Good From The Outset

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced along with the U.S. Department of Health and Human Services (HHS), the deployment of 15 Tablo Hemodialysis Systems to hospitals in Guam that are experiencing a surge in need for acute hemodialysis due to COVID-19. Outset's clinical team and field support staff will accompany the Tabl

Tablo Hemodialysis Systems Deployed to Guam Hospitals by U.S. Department of Health and Human Services for Emergency Response

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2020. Third Quarter 2020 & Recent Highlights Recorded net revenue of $13.8 million in the third quarter of 2020, a 423% increase compared to $2.6 million in the third quarter of 2019 Awarded a second contract from the U.S

Outset Medical Reports Third Quarter 2020 Financial Results

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Steve Williamson as Chief Commercial Officer. In this role, Mr. Williamson will lead Outset's commercial and service organizations as adoption of the Tablo® Hemodialysis System continues to spread rapidly across the full spectrum of dialysis care, from hospitals to

Outset Medical Appoints Steve Williamson as Chief Commercial Officer

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in fireside chats at two upcoming virtual investor conferences. The company will participate in the Morgan Stanley Life After Covid Thematic Conference on Thursday, November 12, 2020 and the Stifel 2020 Virtual Healthcare Conference on Wedn

Outset Medical to Present at Upcoming Virtual Investor Conferences

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Wednesday, November 11, 2020. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chief Executive Officer, and Rebecca Chambers, Chief Financial Officer, will

Outset Medical to Report Third Quarter 2020 Financial Results on Wednesday, November 11, 2020

Outset Medical: Very Interesting MedTech Growth Play

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc.

Outset Medical Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”) today announced the pricing of its upsized initial public offering of 8,951,111 shares of its common stock at a public offering price of $27.00 per share, for total gross proceeds of approximately $241.7 million, before deducting underwriting discounts and commissions and offering expenses.

News for Outset Medical Stock (OM)